Literature DB >> 26873378

Predictors of ertapenem therapeutic efficacy in the treatment of urinary tract infections (UTIs) in hospitalized adults: the importance of renal insufficiency and urinary pH.

B A Cunha1,2, J Giuga3, S Gerson4.   

Abstract

In hospitalized adults acute uncomplicated cystitis (AUC) and catheter associated bacteriuria (CAB) may be treated with oral antibiotics. With AUC or CAB due to extended spectrum ß-lactamase (ESBL) + Gram negative bacilli (GNB) physicians often use intravenous therapy, e.g., ertapenem. We reviewed our recent experience in hospitalized adults with AUC and CAB treated with ertapenem. Therapeutic efficacy of ertapenem was assessed by decreased pyuria/bacteriuria, and elimination of the uropathogen. The effectiveness of ertapenem in the presence of renal insufficiency (CrCl < 50 ml/min) and acid and alkaline urinary pH were evaluated. In addition, rapidity of eradication of bacteriuria was assessed by time to negative urine cultures (TTNC). In those with an acid urinary pH ertapenem was highly effective in eliminating bacteriuria (TTNC < 3 days). TTNC was prolonged ( >3 days) in patients with decreased renal function and alkaline urinary pH. We reviewed 45 hospitalized adults with AUC or CAB to determine if renal insufficiency and or alkaline urinary pH affected ertapenem efficacy. In the 33 adult hospitalized patients with AUC and 12 with CAB, we found that ertapenem was consistently effective in eliminating the GNB bacteriuria. In hospitalized adults, the presence of renal insufficiency and acid urine, bacteriuria was eliminated in < 3 days. However, in those with renal insufficiency and an alkaline urine pH, the rapidity of cure, i.e., time to negative cultures (TTNC) was prolonged, i.e., > 3 days which has not been previously reported.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26873378     DOI: 10.1007/s10096-016-2586-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.

Authors:  Nazan Dalgic; Mesut Sancar; Banu Bayraktar; Emre Dincer; Suleyman Pelit
Journal:  Scand J Infect Dis       Date:  2011-01-28

2.  Comparison of the effectiveness and antibiotic cost among ceftriaxone, ertapenem, and levofloxacin in treatment of community-acquired complicated urinary tract infections.

Authors:  Hsin-An Lin; Ya-Sung Yang; Jing-Xun Wang; Hsin-Chung Lin; De-Yu Lin; Chun-Hsiang Chiu; Kuo-Ming Yeh; Jung-Chung Lin; Feng-Yee Chang
Journal:  J Microbiol Immunol Infect       Date:  2015-01-10       Impact factor: 4.399

3.  Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella pneumoniae.

Authors:  Wonhee So; Jared L Crandon; David P Nicolau
Journal:  J Urol       Date:  2015-01-29       Impact factor: 7.450

4.  Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections.

Authors:  Jian Zhou; Zuraidah Sulaiman; Ryan M Llorin; Kim-Hor Hee; Lawrence Soon-U Lee; David C Lye; Dale A Fisher; Vincent H Tam
Journal:  J Antimicrob Chemother       Date:  2014-05-05       Impact factor: 5.790

Review 5.  Ertapenem. A review of its microbiologic, pharmacokinetic and clinical aspects.

Authors:  Burke A Cunha
Journal:  Drugs Today (Barc)       Date:  2002-03       Impact factor: 2.245

6.  Fluoroquinolone resistance of Serratia marcescens: sucrose, salicylate, temperature, and pH induction of phenotypic resistance.

Authors:  Sanela Begic; Elizabeth A Worobec
Journal:  Can J Microbiol       Date:  2007-11       Impact factor: 2.419

7.  Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers.

Authors:  Dora E Wiskirchen; Seth T Housman; Richard Quintiliani; David P Nicolau; Joseph L Kuti
Journal:  Pharmacotherapy       Date:  2013-02-11       Impact factor: 4.705

8.  The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.

Authors:  Mayuri Trivedi; Mayur Trivedi; Vipul Patel; Rajeev Soman; Camilla Rodriguez; Tanu Singhal
Journal:  J Assoc Physicians India       Date:  2012-08

9.  [Ertapenem administered intravenously or subcutaneously for urinary tract infections caused by ESBL producing enterobacteriacea].

Authors:  E Forestier; S Gros; D Peynaud; M Levast; D Boisseau; C Ferry-Blanco; A Labe; C Lecomte; O Rogeaux
Journal:  Med Mal Infect       Date:  2012-08-25       Impact factor: 2.152

10.  The influence of urinary pH on antibiotic efficacy against bacterial uropathogens.

Authors:  Luo Yang; Kunjie Wang; Hong Li; John D Denstedt; Peter A Cadieux
Journal:  Urology       Date:  2014-09       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.